--- title: "REG - PureTech Health PLC - PDMR Notification RSU Vesting" type: "News" locale: "en" url: "https://longbridge.com/en/news/296253651.md" description: "PureTech Health PLC announced that 33% of Restricted Share Units (RSUs) granted to directors and PDMRs vested on August 1, 2026. Ordinary shares were issued in net settlement on August 17, 2026, after payroll tax retentions. The transaction price was £0.01 per share, with a market reference price of 121.13 pence. Recipients included Eric Elenko, Charles Sherwood, and Michael Inbar, totaling 159,251 ordinary shares issued." datetime: "2026-08-18T16:30:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296253651.md) - [en](https://longbridge.com/en/news/296253651.md) - [zh-HK](https://longbridge.com/zh-HK/news/296253651.md) generator: "portal-rs" --- # REG - PureTech Health PLC - PDMR Notification RSU Vesting RNS Number : 1968R PureTech Health PLC 18 August 2026 18 August 2026 PureTech Health plc PDMR Notifications PureTech Health plc ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that 33% of the shares subject to awards of restricted share units ("RSUs") granted by PureTech on 19 November 2025 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested on 01 August 2026 and were subsequently issued to the PDMRs noted below. Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 17 August 2026. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 121.13 pence, being the average closing price of the Company's shares over the three-trading day period immediately prior to issuance, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.35. The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 12,747,843 shares of which are held in treasury by the Company. PDMR Notification The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Eric Elenko Charles Sherwood Michael Inbar 2 Reason for the notification a) Position/status Eric Elenko - PresidentCharles Sherwood - Chief Operating Officer, General Counsel, and Corporate SecretaryMichael Inbar - Chief Accounting Officer b) Initial notification/Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name PureTech Health plc b) LEI 213800LVPDNO2Z9T9I39 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74 b) Nature of the transaction Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes. c) Price(s) and volume(s) Recipient Price Amount Eric Elenko 0.01 GBP 98,132 ordinary shares Charles Sherwood 0.01 GBP 41,100 ordinary shares Michael Inbar 0.01 GBP 20,019 ordinary shares d) Aggregated information - - - Aggregated volume - - - Price Price Aggregate Volume 0.01 GBP 159,251 ordinary shares e) Date of the transaction 17 August 2026 f) Place of the transaction London Stock Exchange (XLON) About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh. Contact: PureTech Investor Relations IR@puretechhealth.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHGPUBCRUPQGAR ### Related Stocks - [PRTCY.US](https://longbridge.com/en/quote/PRTCY.US.md) - [PRTC.US](https://longbridge.com/en/quote/PRTC.US.md) ## Related News & Research - [REG - PureTech Health PLC - PDMR Notification RSU Vesting](https://longbridge.com/en/news/293058171.md) - [Michele Holcomb Buys 93,944 Shares of PureTech Health (LON:PRTC) Stock](https://longbridge.com/en/news/294571955.md) - [REG - Nationwide B.S. Nationwide BS- 34VG - Results RNS - Re-sale of CCDS](https://longbridge.com/en/news/296240068.md) - [REG - Franklin Templeton Bodycote PLC - Form 8.3 - Bodycote Plc](https://longbridge.com/en/news/296242803.md) - [Exclusive: Fulham launch £900 a head Michelin-guide recognised hospitality at Craven Cottage](https://longbridge.com/en/news/296089846.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**